{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:56:09Z","timestamp":1792806969941,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"am","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005942","name":"Funda\u00e7\u00e3o Butantan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005942","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"publisher","award":["2016\/13134-3"],"award-info":[{"award-number":["2016\/13134-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"publisher","award":["2016\/50296-1"],"award-info":[{"award-number":["2016\/50296-1"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004794","name":"CNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.vaccine.2023.05.031","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T15:35:23Z","timestamp":1684942523000},"page":"4170-4182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immune responses and protection against Streptococcus pneumoniae elicited by recombinant Bordetella pertussis adenylate cyclase (CyaA) carrying fragments of pneumococcal surface protein A, PspA"],"prefix":"10.1016","volume":"41","author":[{"given":"Giovanna Brito","family":"Carneiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Tavares","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyne","family":"Davi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliane Namie","family":"Miyaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ladant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Leonor Sarno","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.05.031_b0005","first-page":"1191","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet","volume":"18","author":"Collaborators GBDLRI","year":"2018","journal-title":"Infect Dis"},{"key":"10.1016\/j.vaccine.2023.05.031_b0010","first-page":"7","article-title":"Pneumococcal Vaccines","author":"Briles","year":"2019","journal-title":"Microbiology spectrum"},{"key":"10.1016\/j.vaccine.2023.05.031_b0015","first-page":"9","article-title":"Pneumococcal vaccines: past findings, present work, and future strategies","author":"Oliveira","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2023.05.031_b0020","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1016\/j.vaccine.2018.04.010","article-title":"Distribution of invasive Streptococcus pneumoniae serotypes before and 5years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil","volume":"36","author":"Brandileone","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.05.031_b0025","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(10)62225-8","article-title":"Serotype replacement in disease after pneumococcal vaccination","volume":"378","author":"Weinberger","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.05.031_b0030","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/INF.0000000000001206","article-title":"Emerging streptococcus pneumoniae strains colonizing the nasopharynx in children after 13-valent pneumococcal conjugate vaccination in comparison to the 7-valent Era, 2006\u20132015","volume":"35","author":"Kaur","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2023.05.031_b0035","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1473-3099(18)30052-5","article-title":"Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000\u201317: a prospective national observational cohort study","volume":"18","author":"Ladhani","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.05.031_b0040","doi-asserted-by":"crossref","first-page":"e1489","DOI":"10.1093\/cid\/ciaa1045","article-title":"Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age","volume":"73","author":"Hurley","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.05.031_b0045","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1080\/21645515.2018.1532249","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults","volume":"15","author":"Stacey","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.05.031_b0050","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.15585\/mmwr.mm7137a3","article-title":"Use of 15-valent pneumococcal conjugate vaccine among U.S. children: updated recommendations of the advisory committee on immunization practices - United States","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.05.031_b0055","doi-asserted-by":"crossref","first-page":"e768","DOI":"10.1093\/cid\/ciaa1480","article-title":"Serotype patterns of pneumococcal disease in adults are correlated with carriage patterns in older children","volume":"72","author":"Wyllie","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.05.031_b0060","doi-asserted-by":"crossref","first-page":"34888","DOI":"10.1038\/srep34888","article-title":"Molecular surveillance on Streptococcus pneumoniae carriage in non-elderly adults; little evidence for pneumococcal circulation independent from the reservoir in children","volume":"6","author":"Wyllie","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.05.031_b0065","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1007\/s00018-012-1234-8","article-title":"Serotype-independent pneumococcal vaccines","volume":"70","author":"Miyaji","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.vaccine.2023.05.031_b0070","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.4049\/jimmunol.1201967","article-title":"Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine","volume":"189","author":"Mukerji","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2023.05.031_b0075","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1128\/IAI.71.1.75-85.2003","article-title":"Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae","volume":"71","author":"Ren","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2023.05.031_b0080","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1128\/IAI.72.9.5031-5040.2004","article-title":"PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected]","volume":"72","author":"Shaper","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2023.05.031_b0085","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1128\/CVI.00134-14","article-title":"Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae","volume":"21","author":"Salcedo-Rivillas","year":"2014","journal-title":"Clinical and Vaccine Immunology : CVI"},{"key":"10.1016\/j.vaccine.2023.05.031_b0090","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2249.2006.03148.x","article-title":"Pneumococcal surface protein A (PspA) is effective at eliciting T cell-mediated responses during invasive pneumococcal disease in adults","volume":"145","author":"Baril","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2023.05.031_b0095","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00281-17","article-title":"Th17-mediated cross protection against pneumococcal carriage by vaccination with a variable antigen","volume":"85","author":"Kuipers","year":"2017","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2023.05.031_b0100","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1086\/317602","article-title":"Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA","volume":"182","author":"Briles","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.05.031_b0105","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1006\/mpat.1994.1078","article-title":"Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260","volume":"17","author":"McDaniel","year":"1994","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2023.05.031_b0110","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1128\/IAI.71.3.1033-1041.2003","article-title":"Regions of PspA\/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection model","volume":"71","author":"Roche","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2023.05.031_b0115","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1128\/IAI.68.10.5889-5900.2000","article-title":"Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae","volume":"68","author":"Hollingshead","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2023.05.031_b0120","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.617573","article-title":"Distribution and variation of serotypes and pneumococcal surface protein a clades of streptococcus pneumoniae strains isolated from adult patients with invasive pneumococcal disease in Japan","volume":"11","author":"Chang","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2023.05.031_b0125","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1099\/jmm.0.46268-0","article-title":"Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries","volume":"55","author":"Hollingshead","year":"2006","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2023.05.031_b0130","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1128\/JCM.00156-06","article-title":"Genetic diversity of PspA types among nasopharyngeal isolates collected during an ongoing surveillance study of children in Brazil","volume":"44","author":"Pimenta","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2023.05.031_b0135","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1128\/CVI.00430-09","article-title":"Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection","volume":"17","author":"Moreno","year":"2010","journal-title":"Clinical and vaccine immunology : CVI"},{"key":"10.1016\/j.vaccine.2023.05.031_b0140","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S0264-410X(99)00530-7","article-title":"Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules","volume":"18","author":"Nabors","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.05.031_b0145","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nrmicro3235","article-title":"Bordetella pertussis pathogenesis: current and future challenges","volume":"12","author":"Melvin","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2023.05.031_b0150","first-page":"10","article-title":"Bioengineering of Bordetella pertussis Adenylate Cyclase Toxin for Antigen-Delivery and Immunotherapy","author":"Chenal","year":"2018","journal-title":"Toxins"},{"key":"10.1016\/j.vaccine.2023.05.031_b0155","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1016\/j.vaccine.2006.02.009","article-title":"Delivery of the HIV-1 Tat protein to dendritic cells by the CyaA vector induces specific Th1 responses and high affinity neutralizing antibodies in non human primates","volume":"24","author":"Mascarell","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.05.031_b0160","doi-asserted-by":"crossref","first-page":"9872","DOI":"10.1128\/JVI.79.15.9872-9884.2005","article-title":"Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis","volume":"79","author":"Mascarell","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.05.031_b0165","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3201\/eid0705.017510","article-title":"Pneumococcal surface protein A of invasive Streptococcus pneumoniae isolates from Colombian children","volume":"7","author":"Vela Coral","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2023.05.031_b0170","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/CVI.00239-14","article-title":"Mapping of epitopes recognized by antibodies induced by immunization of mice with PspA and PspC","volume":"21","author":"Vadesilho","year":"2014","journal-title":"Clinical and Vaccine Immunology : CVI"},{"key":"10.1016\/j.vaccine.2023.05.031_b0175","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1099\/jmm.0.47661-0","article-title":"Recognition of pneumococcal isolates by antisera raised against PspA fragments from different clades","volume":"57","author":"Darrieux","year":"2008","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2023.05.031_b0180","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0076-6879(00)26074-6","article-title":"Bordetella pertussis adenylate cyclase toxin: a vehicle to deliver CD8-positive T-cell epitopes into antigen-presenting cells","volume":"326","author":"Guermonprez","year":"2000","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.vaccine.2023.05.031_b0185","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nmeth.1318","article-title":"Enzymatic assembly of DNA molecules up to several hundred kilobases","volume":"6","author":"Gibson","year":"2009","journal-title":"Nat Methods"},{"key":"10.1016\/j.vaccine.2023.05.031_b0190","doi-asserted-by":"crossref","first-page":"12532","DOI":"10.1073\/pnas.95.21.12532","article-title":"Charge-dependent translocation of Bordetella pertussis adenylate cyclase toxin into eukaryotic cells: implication for the in vivo delivery of CD8(+) T cell epitopes into antigen-presenting cells","volume":"95","author":"Karimova","year":"1998","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2023.05.031_b0195","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1158\/0008-5472.641.65.2","article-title":"Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein","volume":"65","author":"Preville","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2023.05.031_b0200","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1590\/S0100-879X2004000800001","article-title":"A high-copy T7 Escherichia coli expression vector for the production of recombinant proteins with a minimal N-terminal His-tagged fusion peptide","volume":"37","author":"Ramos","year":"2004","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.vaccine.2023.05.031_b0205","doi-asserted-by":"crossref","first-page":"e0173778","DOI":"10.1371\/journal.pone.0173778","article-title":"Optimized Triton X-114 assisted lipopolysaccharide (LPS) removal method reveals the immunomodulatory effect of food proteins","volume":"12","author":"Teodorowicz","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.05.031_b0210","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.micpath.2009.05.005","article-title":"Comparison of the pulmonary response against lethal and non-lethal intranasal challenges with two different pneumococcal strains","volume":"47","author":"Ferreira","year":"2009","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2023.05.031_b0215","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1128\/CVI.00171-12","article-title":"Controlled inflammatory responses in the lungs are associated with protection elicited by a pneumococcal surface protein a-based vaccine against a lethal respiratory challenge with streptococcus pneumoniae in mice","volume":"19","author":"Lima","year":"2012","journal-title":"Clinical and Vaccine Immunology : CVI"},{"key":"10.1016\/j.vaccine.2023.05.031_b0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010863","article-title":"Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice","volume":"5","author":"Oliveira","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.05.031_b0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170157","article-title":"Protection elicited by nasal immunization with recombinant pneumococcal surface protein a (rPspA) adjuvanted with whole-cell pertussis vaccine (wP) against co-colonization of mice with streptococcus pneumoniae","volume":"12","author":"Tostes","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.05.031_b0230","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.01360-10","article-title":"Nasal dendritic cell targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia","author":"Kataoka","year":"2011","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2023.05.031_b0235","doi-asserted-by":"crossref","first-page":"7944","DOI":"10.1073\/pnas.93.15.7944","article-title":"Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis","volume":"93","author":"Renauld-Mongenie","year":"1996","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2023.05.031_b0240","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1016\/j.vaccine.2004.04.033","article-title":"Adjuvanticity of native and detoxified adenylate cyclase toxin of Bordetella pertussis towards co-administered antigens","volume":"22","author":"Macdonald-Fyall","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.05.031_b0245","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1073\/pnas.94.7.3314","article-title":"Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis virus","volume":"94","author":"Saron","year":"1997","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2023.05.031_b0250","doi-asserted-by":"crossref","first-page":"e0174038","DOI":"10.1371\/journal.pone.0174038","article-title":"GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression","volume":"12","author":"Esquerre","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.05.031_b0255","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1158\/1078-0432.CCR-16-0085","article-title":"GTL001, a therapeutic vaccine for women infected with human papillomavirus 16 or 18 and normal cervical cytology: results of a phase I clinical trial","volume":"22","author":"Van Damme","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2023.05.031_b0260","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1128\/CVI.00400-07","article-title":"Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)\/IgG2a ratio and proinflammatory cytokine production","volume":"15","author":"Ferreira","year":"2008","journal-title":"Clinical and Vaccine Immunology : CVI"},{"key":"10.1016\/j.vaccine.2023.05.031_b0265","doi-asserted-by":"crossref","first-page":"6718","DOI":"10.1128\/IAI.69.11.6718-6724.2001","article-title":"Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection","volume":"69","author":"Arulanandam","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2023.05.031_b0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007438","article-title":"Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci","volume":"14","author":"Azarian","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2023.05.031_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109267","article-title":"Streptococcus pneumoniae binds to host GAPDH on dying lung epithelial cells worsening secondary infection following influenza","volume":"35","author":"Park","year":"2021","journal-title":"Cell Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23005704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23005704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:45:50Z","timestamp":1778737550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23005704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":55,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0264410X23005704"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.05.031","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune responses and protection against Streptococcus pneumoniae elicited by recombinant Bordetella pertussis adenylate cyclase (CyaA) carrying fragments of pneumococcal surface protein A, PspA","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.05.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}